Reaction from the British Generic Manufacturers Association (BGMA) to the Government’s future partnership paper outlining how continued collaboration in science and innovation is an important part of the UK’s future partnership with the EU.
Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “We welcome the sentiment of continued collaboration and partnership with the EU which the Government has laid out in its science and innovation paper. A close working relationship with our European partners, is in the interests of public health and patient safety for all European citizens and in our view is paramount. We particularly welcome the commitment to continue to work closely with the EMA and other international partners.
“As part of the on-going Brexit negotiations, we have consistently stated that the existence of a close EU-UK regulatory system for medicines has generated considerable benefits for patients, the NHS and the industry. This has helped reduce costs and delays in getting medicines on to the market. We have urged both sides in the Brexit negotiations to find a way of maintaining these benefits in the interests of their citizens.”
For further information contact Jeremy Durrant on 020 7866 7883 or email Jeremy.firstname.lastname@example.org
For more information on the BGMA, visit: www.britishgenerics.co.uk.